Macrogenics Stock Today
| MGNX Stock | USD 3.21 0.07 2.13% |
Performance0 of 100
| Odds Of DistressOver 64
|
MacroGenics is trading at 3.21 as of the 21st of November 2024; that is 2.13 percent decrease since the beginning of the trading day. The stock's open price was 3.28. MacroGenics has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for MacroGenics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2013 | Category Healthcare | Classification Health Care |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 62.76 M outstanding shares of which 5.46 M shares are now shorted by private and institutional investors with about 10.07 trading days to cover. More on MacroGenics
Moving against MacroGenics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
MacroGenics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Scott MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMacroGenics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MacroGenics' financial leverage. It provides some insight into what part of MacroGenics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MacroGenics (MGNX) is traded on NASDAQ Exchange in USA. It is located in 9704 Medical Center Drive, Rockville, MD, United States, 20850 and employs 339 people. MacroGenics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 205.86 M. MacroGenics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 62.76 M outstanding shares of which 5.46 M shares are now shorted by private and institutional investors with about 10.07 trading days to cover.
MacroGenics currently holds about 133.74 M in cash with (78.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18.
Check MacroGenics Probability Of Bankruptcy
Ownership AllocationMacroGenics maintains a total of 62.76 Million outstanding shares. The majority of MacroGenics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MacroGenics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MacroGenics. Please pay attention to any change in the institutional holdings of MacroGenics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MacroGenics Ownership Details
MacroGenics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-06-30 | 1.2 M | |
| Rock Springs Capital Management Lp | 2024-06-30 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 944.5 K | |
| Hudson Bay Capital Management Lp | 2024-06-30 | 916.5 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 882.7 K | |
| Vestal Point Capital Lp | 2024-06-30 | 800 K | |
| Northern Trust Corp | 2024-09-30 | 702.8 K | |
| Pinnacle Associates Inc | 2024-09-30 | 688 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 658 K | |
| Bellevue Group Ag | 2024-09-30 | 9.9 M | |
| Armistice Capital, Llc | 2024-06-30 | 6 M |
MacroGenics Historical Income Statement
MacroGenics Stock Against Markets
MacroGenics Corporate Executives
Elected by the shareholders, the MacroGenics' board of directors comprises two types of representatives: MacroGenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MacroGenics. The board's role is to monitor MacroGenics' management team and ensure that shareholders' interests are well served. MacroGenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MacroGenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Karrels | CFO, Sr. VP and Corporate Secretary | Profile |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.